For the Quarter Ending September 2025
North America
• In United States, the Moxifloxacin Hydrochloride Price Index rose quarter-over-quarter in Q3 2025, driven by escalating production costs.
• Rising CPI (3.0% in September 2025) and PPI (2.6% in August 2025) indicated higher operational costs for producers.
• US tariffs on pharmaceutical imports, effective July 2025, significantly elevated API input costs for manufacturers.
• Healthcare service demand experienced sustained growth in Q3 2025, supporting Moxifloxacin Hydrochloride consumption and demand.
• Strong retail sales (5.42% in September 2025) and low unemployment (4.3% in September 2025) bolstered patient access.
• Raw material inventories for chemical manufacturers contracted or remained stable in Q3 2025, tightening supply.
• US pharmaceutical imports notably decreased in July-August 2025, influenced by new tariffs.
• Henry Hub natural gas spot prices began to rise in September 2025, increasing energy-related production expenses.
• The pharmaceutical market size was expanding in 2025, indicating a favorable long-term demand outlook.
Why did the price of Moxifloxacin Hydrochloride change in September 2025 in North America?
• Rising CPI (3.0% in September 2025) increased operational costs for Moxifloxacin Hydrochloride production.
• New US tariffs on pharmaceutical imports, effective July 2025, elevated API input costs for manufacturers.
• Henry Hub natural gas spot prices began to rise in September 2025, impacting energy expenses.
APAC
• In China, the Moxifloxacin Hydrochloride Price Index fell quarter-over-quarter in Q3 2025, influenced by weakened industrial demand.
• Moxifloxacin Hydrochloride production costs decreased in Q3 2025 due to softened acetic acid and benzene feedstock prices.
• Overall healthcare demand strengthened in Q3 2025, supported by a stable 5.2% unemployment rate in September 2025.
• China's Manufacturing Index was contracting in September 2025, signaling broader economic weakness impacting the supply chain.
• Industrial production increased 6.5% year-on-year in September 2025, indicating robust manufacturing activity for chemical inputs.
• Retail sales grew 3.0% year-on-year in September 2025, yet consumer confidence remained pessimistic at 89.6.
• The Consumer Price Index decreased 0.3% year-on-year in September 2025, reflecting deflationary pressures and reduced purchasing power.
• Persistent overcapacity in China's chemical industry and new acetic acid additions outpaced demand in Q3 2025.
Why did the price of Moxifloxacin Hydrochloride change in September 2025 in APAC?
• Falling factory-gate prices, indicated by a 2.3% year-on-year PPI decrease in September 2025, pressured Moxifloxacin Hydrochloride pricing.
• Softened acetic acid and benzene feedstock costs in Q3 2025 reduced production expenses for Moxifloxacin Hydrochloride manufacturers.
• A contracting Manufacturing Index in September 2025 signaled weak industrial demand, contributing to overall price pressure.
Europe
• In Germany, the Moxifloxacin Hydrochloride Price Index remained stable quarter-over-quarter in Q3 2025, amidst mixed economic signals.
• Moxifloxacin Hydrochloride production costs faced upward pressure from a 2.4% CPI YoY in September 2025, increasing operational expenses.
• Conversely, a -1.7% PPI YoY in September 2025 suggested falling producer prices, potentially lowering raw material input costs.
• Demand for Moxifloxacin Hydrochloride was supported by Germany's expanding pharmaceutical market in Q3 2025.
• The Manufacturing Index contracted in September 2025, indicating a slowdown in industrial activity affecting supply chains.
• Industrial production declined by 1.0% YoY in September 2025, impacting raw material availability for Moxifloxacin Hydrochloride.
• Elevated electricity prices for German businesses in Q3 2025 contributed to persistent production cost challenges.
• Germany's pharmaceutical imports increased substantially in Q3 2025, influencing Moxifloxacin Hydrochloride trade flows.
• A low unemployment rate of 3.9% in September 2025 indirectly supported healthcare funding and patient access.
Why did the price of Moxifloxacin Hydrochloride change in September 2025 in Europe?
• Elevated energy and raw material costs in Q3 2025 pressured Moxifloxacin Hydrochloride production expenses.
• Increased pharmaceutical imports into Germany during Q3 2025 influenced Moxifloxacin Hydrochloride market dynamics.
• A contracting Manufacturing Index in September 2025 indicated broader industrial slowdown, affecting supply chain stability.
For the Quarter Ending December 2022
North America
The price of Moxifloxacin Hydrochloride in North America increased gradually over the first part of the fourth quarter of 2022. End-user demand from the pharmaceutical sector kept the Moxifloxacin Hydrochloride prices on the higher side.
Furthermore, Supply chain disruption decreased rapidly over the six months to November across multiple measures, including shipping prices, which supported the positive market trend of Moxifloxacin Hydrochloride. Until November, the prices of Moxifloxacin Hydrochloride remained on the North side and were recorded at USD 207450/MT CFR New York, but then it began to collapse at the start of December owing to a significant drop in its offtakes.
APAC
Moxifloxacin Hydrochloride prices plummet during the fourth quarter of 2022 in the Asia Pacific region, particularly in China. Although during the first half of q4, the prices remained on the positive side owing to healthy downstream demand balanced with the supplies among the market players. However, the ease in supply chain disruption, including shipping prices, during November compared to October somewhat helped the traders and suppliers to get more orders and balance the demand side. With the end of the year 2022, China's production activities began to decrease noticeably after November a surge in COVID-19 cases, owing to which the trade momentum weakened along with the decrease in freight charges which positively supported the price trend of Moxifloxacin Hydrochloride. Overall, the price of Moxifloxacin Hydrochloride noted in the mid of the fourth quarter was assembled at USD 182010/MT FOB Shanghai.
Europe
In the fourth quarter of 2022, the European market for Moxifloxacin Hydrochloride followed a similar pattern to that of Asia Pacific. The market trend initially began on a good note up to November and reached an assembly price of USD 215250/MT CFR Hamburg in Germany because of increased demand from the end-user pharmaceutical industry. As inquiries from the downstream sector for Moxifloxacin Hydrochloride prices began to fall significantly after December, supporting the weaker price trend of Moxifloxacin Hydrochloride as the market participants had abundant supplies with little or no demand. In addition, fresher orders declined in December due to suppliers having large stock levels due to the market's brief closure.
For the Quarter Ending September 2022
North America
In North America, the price of Moxifloxacin HCL witnessed an inclined market sentiment backed by heightened downstream demand from end-user sectors. At the onset of the first half of the third quarter, the prices went high following higher downstream demand for the treatment of antibacterial infections. Further mimicking a similar trend, the values upsurged significantly in the mid of Q3, with an overall percentage of 5.78 in the United States. Additionally, halted trading activities from various exporting countries affected the market sentiments in the region. With this, Towards the termination of Q3, the prices witnessed for Moxifloxacin Hydrochloride were settled at USD 200000/MT CFR New York.
Asia Pacific
In the third quarter of 2022, the prices of Moxifloxacin HCL in the APAC region witnessed an incremented state backed by higher customer inquiries. During the first half of Q3, the prices went high, which was supported by higher demand and a weakened supply side. Followed by the previous month, the prices for Moxifloxacin Hydrochloride rose significantly, with an overall inclination of 10.30 percent due to the increase in various bacterial infections. Meanwhile, its demand in the Indian market also surged during the mid of q3, and the export momentum witnessed was disrupted, leading to delayed consignments, impacting the market sentiments of Moxifloxacin HCL in the region. Moreover, compared to previous months, the prices witnessed for Moxifloxacin Hydrochloride towards the termination of Q3 were settled at USD 175950/MT FOB Shanghai with a declined trend.
Europe
In the European region, the price for Moxifloxacin Hydrochloride followed the Asian market, as it mainly depended on the import market during the third quarter of 2022. Its downstream demand from the domestic market kept moving upward as offtakes from the Pharma sector increased during the first two months of Q3. Owing to its major application in treating bacterial infections, the demand for treatment remained on the higher side. Furthermore, port congestion delayed shipments, and rerouting activities further led to the rising price trend. Moreover, towards the termination of Q3, the prices witnessed for Moxifloxacin Hydrochloride were settled at USD 207390 /MT CFR Hamburg.
For the Quarter Ending June 2022
North America
In North America, the price of moxifloxacin HCL increased slightly in the first half of the second quarter, which then rose significantly following higher downstream demand for the treatment of antibacterial infections. The shortage of supply supported by the lack of upstream feed sulfonic acid in the market affected the value of the API price. The costs of upstream sulfonic acid have increased both regionally and domestically due to high offtakes for treating respiratory Tract Infections (RTI), pneumonia, skin, and abdominal infections. However, the reduction of stocks and insufficient availability of raw materials on the market led producers to increase production amid higher feed costs. In addition, the fluctuating oil prices also contributed to the increase in the prices of moxifloxacin HCL. Towards the termination of Q2 the prices witnessed for Moxifloxacin Hydrochloride were settled at USD 175760/MT CRR New York.
APAC
Moxifloxacin HCL finds its application in various bacterial infections like pneumonia, skin, and abdominal infections. Its prices are mainly based on demand fundamentals which remained high during the second half of Q2. The first half observed a lull due to the covid-19 resurgence in the domestic market, contributing to the low offtakes from the pharma sector. Meanwhile, its demand picked up in India during the second half as export demand improved alongside soaring feedstock Sulfonic Acid. Traders even noticed port congestion, delayed delivery of goods, and rising freight cost. After considering these factors, the manufacturers were forced to revise their margins, leading to an incline in the price trend. Towards the termination of Q2 the prices witnessed for Moxifloxacin Hydrochloride were settled at USD 159900/MT FOB Shanghai.
Europe
In Europe, the price for Moxifloxacin followed the Asian market, as it mainly depends on the import market. Its demand from the domestic market kept moving upward as offtakes from the Pharma sector increased during the considerable period. Meantime, Moxifloxacin HCL is mainly used to treat pneumonia, skin, and abdominal infections. Therefore, the demand for the treatment of bacterial infections remains high. At the same time, soaring feedstock Sulfonic acid also contributed to the rising price trend. Furthermore, rising freight charges and congestion in port further led to the rising price trend. However, the producers increased their output due to the market's inadequate feedstock stockpiles and reduced supply. Towards the termination of Q2 the prices witnessed for Moxifloxacin Hydrochloride were settled at USD 186470/MT CFR Hamburg.
